These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 23602690)
41. Polypharmacy in schizophrenia. Baandrup L Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):183-192. PubMed ID: 31908124 [TBL] [Abstract][Full Text] [Related]
42. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Basan A; Kissling W; Leucht S Schizophr Res; 2004 Sep; 70(1):33-7. PubMed ID: 15246461 [TBL] [Abstract][Full Text] [Related]
43. Benzodiazepines as adjunctive therapy in treatment refractory symptoms of schizophrenia. Szarmach J; Włodarczyk A; Cubała WJ; Wiglusz MS Psychiatr Danub; 2017 Sep; 29(Suppl 3):349-352. PubMed ID: 28953789 [TBL] [Abstract][Full Text] [Related]
44. The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis. Kopelli E; Samara M; Siargkas A; Goulas A; Papazisis G; Chourdakis M Psychiatry Res; 2020 Sep; 291():113246. PubMed ID: 32599446 [TBL] [Abstract][Full Text] [Related]
45. A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects. Chen AT; Chibnall JT; Nasrallah HA Ann Clin Psychiatry; 2015 Nov; 27(4):289-96. PubMed ID: 26554370 [TBL] [Abstract][Full Text] [Related]
46. Practical pharmacotherapy for acute schizophrenia patients. Hatta K Psychiatry Clin Neurosci; 2015 Nov; 69(11):674-85. PubMed ID: 26037685 [TBL] [Abstract][Full Text] [Related]
47. Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study. Fontanella CA; Campo JV; Phillips GS; Hiance-Steelesmith DL; Sweeney HA; Tam K; Lehrer D; Klein R; Hurst M J Clin Psychiatry; 2016 May; 77(5):661-7. PubMed ID: 27249075 [TBL] [Abstract][Full Text] [Related]
48. Chemical agents for the sedation of agitated patients in the ED: a systematic review. Korczak V; Kirby A; Gunja N Am J Emerg Med; 2016 Dec; 34(12):2426-2431. PubMed ID: 27707527 [TBL] [Abstract][Full Text] [Related]
50. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Rabinowitz J; Levine SZ; Barkai O; Davidov O Schizophr Bull; 2009 Jul; 35(4):775-88. PubMed ID: 18303093 [TBL] [Abstract][Full Text] [Related]
51. Adjunctive benzodiazepine treatment of hospitalized schizophrenia patients in Asia from 2001 to 2008. Tor PC; Ng TP; Yong KH; Sim K; Xiang YT; Wang CY; Lee EH; Fujii S; Yang SY; Chong MY; Ungvari GS; Si T; He YL; Chung EK; Chee KY; Trivedi J; Udomratn P; Shinfuku N; Kua EH; Tan CH; Sartorius N; Baldessarini RJ Int J Neuropsychopharmacol; 2011 Jul; 14(6):735-45. PubMed ID: 21294941 [TBL] [Abstract][Full Text] [Related]
52. Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Okuyama Y; Oya K; Matsunaga S; Kishi T; Iwata N Neuropsychiatr Dis Treat; 2016; 12():3221-3236. PubMed ID: 28008259 [TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: an updated meta-analysis of randomized placebo-controlled trials. Matsuda Y; Kishi T; Iwata N J Psychiatr Res; 2013 Dec; 47(12):2018-20. PubMed ID: 24079776 [No Abstract] [Full Text] [Related]
54. Memantine as an Augmentation Treatment for Schizophrenia: Limitations of Meta-Analysis for Evidence-Based Evaluation of Research. Andrade C J Clin Psychiatry; 2017; 78(9):e1307-e1309. PubMed ID: 29178686 [TBL] [Abstract][Full Text] [Related]
55. [Polypharmacy in schizophrenia]. Zink M; Englisch S; Meyer-Lindenberg A Nervenarzt; 2011 Jul; 82(7):853-8. PubMed ID: 21165589 [TBL] [Abstract][Full Text] [Related]
56. Antipsychotic and benzodiazepine use and brain morphology in schizophrenia and affective psychoses - Systematic reviews and birth cohort study. Huhtaniska S; Korkala I; Heikka T; Björnholm L; Lehtiniemi H; Hulkko AP; Moilanen J; Tohka J; Manjón J; Coupé P; Kiviniemi V; Isohanni M; Koponen H; Murray GK; Miettunen J; Jääskeläinen E Psychiatry Res Neuroimaging; 2018 Nov; 281():43-52. PubMed ID: 30219591 [TBL] [Abstract][Full Text] [Related]
57. Risks and benefits of bupropion treatment in schizophrenia: a systematic review of the current literature. Englisch S; Morgen K; Meyer-Lindenberg A; Zink M Clin Neuropharmacol; 2013; 36(6):203-15. PubMed ID: 24201231 [TBL] [Abstract][Full Text] [Related]
58. Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review. Heringa SM; Begemann MJ; Goverde AJ; Sommer IE Schizophr Res; 2015 Nov; 168(3):603-13. PubMed ID: 25914107 [TBL] [Abstract][Full Text] [Related]
59. Pharmacological treatment of schizophrenia with comorbid substance use disorder. Azorin JM; Simon N; Adida M; Belzeaux R Expert Opin Pharmacother; 2016; 17(2):231-53. PubMed ID: 26635059 [TBL] [Abstract][Full Text] [Related]
60. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. Galling B; Roldán A; Hagi K; Rietschel L; Walyzada F; Zheng W; Cao XL; Xiang YT; Zink M; Kane JM; Nielsen J; Leucht S; Correll CU World Psychiatry; 2017 Feb; 16(1):77-89. PubMed ID: 28127934 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]